INNOCAN PHARMA Corp

INNOCAN PHARMA Corp (INNP) showed no cyber incidents or material red-flag 8-K filings in our 90-day monitoring window, suggesting recent operational stability. However, low signal in a short timeframe does not indicate absence of risk; biotech companies face persistent dilution, financing, and regulatory pressures that require deeper analysis. The full $49 Report extends coverage to 12 months of filings, applies our dilution risk scoring model, maps the company's financing history and burn trajectory, and flags AI-detected anomalies in disclosure patterns. The full $49 Report adds comprehensive dilution metrics, complete 8-K context, and forward risk signals based on 12 months of SEC data.